LEO Pharma entered into a license/collaboration with Boehringer Ingelheim in a license/collaboration on not available.
Deal value was 3100000000 Sector: Pharmaceuticals; Location: Global.
On the acquirer side, counsel was not available, led by Shellie Freedman, Joanna Schlingbaum, Frank Gallina, Duncan Enista.
Generated by AI, original source from - Data is in progress
Boehringer Ingelheim advisor
Firm name is in progress
Found it useful? Spread the word.
Kirkland & Ellis advises LEO Pharma (Nordic Capital) on exclusive global license agreement with Boehringer Ingelheim for SPEVIGO | The Sponsor - The Sponsor
